August 10, 2011Open Access

Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group

JMJudith ManolaDana-Farber Cancer Institute PRPatrick RoystonUniversité Claude Bernard Lyon 1 PEPaul ElsonCleveland Clinic

Key Points

Key points are not available for this paper at this time.

Abstract

Nine clinical factors can be used to model survival in mRCC and form distinct prognostic groups. The model shows utility among patients treated in the TKI era.

AIに質問

Bookmark

View Full Paper

Cite This Study

Manola et al. (Wed,) studied this question.

synapsesocial.com/papers/69dcf87ae3a90a2e2f1335fd https://doi.org/https://doi.org/10.1158/1078-0432.ccr-11-0553

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma2010 · 157 citations
2Phase 3 trial of everolimus for metastatic renal cell carcinoma2010 · 1,145 citations
3Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect2006 · 1,185 citations
4Building Multivariable Regression Models with Continuous Covariates in Clinical Epidemiology2005 · 195 citations
5Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study2009 · 2,136 citations

AIに質問

Bookmark

View Full Paper